Pub Date : 2011-12-30DOI: 10.2174/1875043501104010054
Yasumasa Kuroda, M. Kitada, Shohei Wakao, M. Dezawa
Schwann cells are important components of the peripheral glia that form myelin, serving as the microenvironment of nerve fibers in the peripheral nervous system (PNS). Damage to the PNS induces the differentiation and activation of Schwann cells to produce factors that strongly promote axonal regrowth, and subsequently contribute to remyelination, which is crucial for the recovery of function. Although the collection and transplantation of native Schwann cells are effective for the treatment of neural diseases, isolation of Schwann cells results in new damage to other peripheral nerve segments and causes undesirable iatrogenic injury in the donor. Furthermore, the expansion of native Schwann cells to obtain a sufficient number of cells for clinical application within a reasonable period is technically difficult. Therefore, a method to induce easily accessible and highly proliferative cells to differentiate into cells with Schwann cell properties would be very practical and is highly desirable. Recently, regenerative medicine has focused on mesenchymal stem cells because they are easily accessible from various kinds of mesenchymal tissues such as the umbilical cord, bone marrow, and fat tissue. Mesenchymal stem cells are highly proliferative and it is easy to obtain an adequate number of cells. Notably, while mesenchymal stem cells are mesodermal lineage cells, they have an ability to cross oligolineage boundaries previously thought uncrossable to achieve transdifferentiation. In this review, we focus on the potential of mesenchymal stem cells, particularly umbilical cord-derived mesenchymal stem cells, to differentiate into functional Schwann cells, and discuss the prospective clinical application of these cells to PNS regeneration.
{"title":"Mesenchymal Stem Cells and Umbilical Cord as Sources for Schwann CellDifferentiation: their Potential in Peripheral Nerve Repair","authors":"Yasumasa Kuroda, M. Kitada, Shohei Wakao, M. Dezawa","doi":"10.2174/1875043501104010054","DOIUrl":"https://doi.org/10.2174/1875043501104010054","url":null,"abstract":"Schwann cells are important components of the peripheral glia that form myelin, serving as the microenvironment of nerve fibers in the peripheral nervous system (PNS). Damage to the PNS induces the differentiation and activation of Schwann cells to produce factors that strongly promote axonal regrowth, and subsequently contribute to remyelination, which is crucial for the recovery of function. Although the collection and transplantation of native Schwann cells are effective for the treatment of neural diseases, isolation of Schwann cells results in new damage to other peripheral nerve segments and causes undesirable iatrogenic injury in the donor. Furthermore, the expansion of native Schwann cells to obtain a sufficient number of cells for clinical application within a reasonable period is technically difficult. Therefore, a method to induce easily accessible and highly proliferative cells to differentiate into cells with Schwann cell properties would be very practical and is highly desirable. Recently, regenerative medicine has focused on mesenchymal stem cells because they are easily accessible from various kinds of mesenchymal tissues such as the umbilical cord, bone marrow, and fat tissue. Mesenchymal stem cells are highly proliferative and it is easy to obtain an adequate number of cells. Notably, while mesenchymal stem cells are mesodermal lineage cells, they have an ability to cross oligolineage boundaries previously thought uncrossable to achieve transdifferentiation. In this review, we focus on the potential of mesenchymal stem cells, particularly umbilical cord-derived mesenchymal stem cells, to differentiate into functional Schwann cells, and discuss the prospective clinical application of these cells to PNS regeneration.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"4 1","pages":"54-63"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68109051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-12-30DOI: 10.2174/1875043501104010064
O. Semenov, C. Breymann
Experimental results accumulated during last decade suggest that human perinatal tissues such as placenta, fetal membranes, and umbilical cord, as well as perinatal fluids such as, amniotic fluid and umbilical cord blood, harbour different amounts of multipotent precursor cells, called extra-embryonic mesenchymal stem cells (EE-MSCs). Perinatal EE-MSCs represent an intermediate cell type between pluripotent embryonic stem cells (ESCs) and multipotent MSCs derived from variety of postnatal human tissues, such as bone marrow, fat, dental pulp, etc. Multipotent mesenchymal cells obtained from connective Whartons Jelly tissue of umbilical cord (WJ-MSCs) currently emerged as particularly interesting type of perinatal EE-MSCs, related for therapeutical applications and cryobanking. These cells are easily assessable for isolation, possess fetal karyotype, and hold very active growth potential. Due to their unique developmental position WJ-MSCs exhibit specific phenotype which combines some markers expressed by postnatal bone marrow- derived MSCs, such as CD73, CD90, and CD105 with some markers typically expressed by ESCs, such as Oct-3/4, Sox- 2, and Nanog. In terms of plasticity WJ-MSCs demonstrate the potential for differentiation towards mesodermal and ectodermal lineages in vitro and in vivo. Additionally, extraembryonic tissues are normally discarded after birth and the isolation of WJ-MSCs is free of ethical concerns. In this work we aim to review previously obtained experimental results, discuss different aspects concerning plasticity and immunomodulatory characteristics of WJ-MSCs, and evaluate the potential of these cells for biomedical and clinical applications.
{"title":"Mesenchymal Stem Cells Derived from Wharton's Jelly and their Potential for Cardio-Vascular Tissue Engineering","authors":"O. Semenov, C. Breymann","doi":"10.2174/1875043501104010064","DOIUrl":"https://doi.org/10.2174/1875043501104010064","url":null,"abstract":"Experimental results accumulated during last decade suggest that human perinatal tissues such as placenta, fetal membranes, and umbilical cord, as well as perinatal fluids such as, amniotic fluid and umbilical cord blood, harbour different amounts of multipotent precursor cells, called extra-embryonic mesenchymal stem cells (EE-MSCs). Perinatal EE-MSCs represent an intermediate cell type between pluripotent embryonic stem cells (ESCs) and multipotent MSCs derived from variety of postnatal human tissues, such as bone marrow, fat, dental pulp, etc. Multipotent mesenchymal cells obtained from connective Whartons Jelly tissue of umbilical cord (WJ-MSCs) currently emerged as particularly interesting type of perinatal EE-MSCs, related for therapeutical applications and cryobanking. These cells are easily assessable for isolation, possess fetal karyotype, and hold very active growth potential. Due to their unique developmental position WJ-MSCs exhibit specific phenotype which combines some markers expressed by postnatal bone marrow- derived MSCs, such as CD73, CD90, and CD105 with some markers typically expressed by ESCs, such as Oct-3/4, Sox- 2, and Nanog. In terms of plasticity WJ-MSCs demonstrate the potential for differentiation towards mesodermal and ectodermal lineages in vitro and in vivo. Additionally, extraembryonic tissues are normally discarded after birth and the isolation of WJ-MSCs is free of ethical concerns. In this work we aim to review previously obtained experimental results, discuss different aspects concerning plasticity and immunomodulatory characteristics of WJ-MSCs, and evaluate the potential of these cells for biomedical and clinical applications.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"4 1","pages":"64-71"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68109064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-12-30DOI: 10.2174/1875043501104010082
Yelica López, Kiran Seshareddy, Elizabeth M. Trevino, Josiah Cox, M. Weiss
Isolates of mesenchymal stromal cells (MSCs) contain a mixed cell population of stem cells, multipotent and unipotent progenitors, and differentiated cells. It is speculated that the useful subpopulation for tissue engineering and cell therapy will be the multipotent progenitor cells or the stem cells. The colony forming unit-fibroblast (CFU-F) assay is an in vitro assay for clonogenicity, which is one property of the stem/progenitor cell population of MSCs. Our goal was to generate standard protocols that would permit the expansion and maintenance of CFU-F. Previous work reported that low plating density and/or exposure to 5% oxygen vs. 21% oxygen increased proliferation rate and enhanced expansion of MSCs. Here, we characterized the effect of both plating density and oxygen concentration on MSCs derived from Wharton's jelly (WJCs). We found that reducing oxygen concentration from 21% (room air) to 5% during expansion increased cell yield and maintained CFU-F, without affecting the expression of surface markers or the differentiation capacity of WJCs. In addition, reducing plating density from 100 cells/cm 2 to 10 cells/cm 2 increased CFU-F frequency. Therefore, plating density and oxygen concentration are two important variables that affect the expansion rate and frequency of CFU-F of WJCs. These results suggest that these two variables might be used to produce different input populations for tissue engineering or cellular therapy.
{"title":"Evaluating the Impact of Oxygen Concentration and Plating Density on Human Wharton's Jelly-Derived Mesenchymal Stromal Cells","authors":"Yelica López, Kiran Seshareddy, Elizabeth M. Trevino, Josiah Cox, M. Weiss","doi":"10.2174/1875043501104010082","DOIUrl":"https://doi.org/10.2174/1875043501104010082","url":null,"abstract":"Isolates of mesenchymal stromal cells (MSCs) contain a mixed cell population of stem cells, multipotent and unipotent progenitors, and differentiated cells. It is speculated that the useful subpopulation for tissue engineering and cell therapy will be the multipotent progenitor cells or the stem cells. The colony forming unit-fibroblast (CFU-F) assay is an in vitro assay for clonogenicity, which is one property of the stem/progenitor cell population of MSCs. Our goal was to generate standard protocols that would permit the expansion and maintenance of CFU-F. Previous work reported that low plating density and/or exposure to 5% oxygen vs. 21% oxygen increased proliferation rate and enhanced expansion of MSCs. Here, we characterized the effect of both plating density and oxygen concentration on MSCs derived from Wharton's jelly (WJCs). We found that reducing oxygen concentration from 21% (room air) to 5% during expansion increased cell yield and maintained CFU-F, without affecting the expression of surface markers or the differentiation capacity of WJCs. In addition, reducing plating density from 100 cells/cm 2 to 10 cells/cm 2 increased CFU-F frequency. Therefore, plating density and oxygen concentration are two important variables that affect the expansion rate and frequency of CFU-F of WJCs. These results suggest that these two variables might be used to produce different input populations for tissue engineering or cellular therapy.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"4 1","pages":"82-94"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68108556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-12-30DOI: 10.2174/1875043501104010048
I. Scheers, C. Lombard, M. Najimi, E. Sokal
Cell therapy has emerged as an attractive alternative to orthotopic liver transplantation for the treatment of liver disease. Among the potential candidates, umbilical cord derived stem cells are of particular interest owing to greater proliferation potential and low immunoreactivity. Previous reports permit to distinguish different cell types that could be generated from cord blood, vessels and cord matrix itself. Wharton Jelly's derived umbilical cord stem cells and cord- blood derived mesenchymal stem cells have demonstrated a potential to differentiate into endodermal lineage, including hepatocyte-like cells. In addition, recent studies have underlined their potential to alleviate liver fibrosis and express liver metabolic functions in rodent models. The present review focuses on the current knowledge on in vitro and in vivo use of these cells for liver cell therapy. We discuss the general characteristics homology between hepatic and umbilical cord derived stem cells and the results of hepatocyte-like differentiation attempts. We finally address the question of future application of these cells for the treatment of liver disease.
{"title":"Cell Therapy for the Treatment of Metabolic Liver Disease: An Update on the Umbilical Cord Derived Stem Cells Candidates","authors":"I. Scheers, C. Lombard, M. Najimi, E. Sokal","doi":"10.2174/1875043501104010048","DOIUrl":"https://doi.org/10.2174/1875043501104010048","url":null,"abstract":"Cell therapy has emerged as an attractive alternative to orthotopic liver transplantation for the treatment of liver disease. Among the potential candidates, umbilical cord derived stem cells are of particular interest owing to greater proliferation potential and low immunoreactivity. Previous reports permit to distinguish different cell types that could be generated from cord blood, vessels and cord matrix itself. Wharton Jelly's derived umbilical cord stem cells and cord- blood derived mesenchymal stem cells have demonstrated a potential to differentiate into endodermal lineage, including hepatocyte-like cells. In addition, recent studies have underlined their potential to alleviate liver fibrosis and express liver metabolic functions in rodent models. The present review focuses on the current knowledge on in vitro and in vivo use of these cells for liver cell therapy. We discuss the general characteristics homology between hepatic and umbilical cord derived stem cells and the results of hepatocyte-like differentiation attempts. We finally address the question of future application of these cells for the treatment of liver disease.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"4 1","pages":"48-53"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68109013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-12-30DOI: 10.2174/1875043501104010120
A. Lange-Consiglio, B. Corradetti, L. Rutigliano, F. Cremonesi, D. Bizzaro
Despite the increasing use of cell-based therapies for equine orthopedic problems, many questions remain to be answered, such as what is: the optimal cell source for particular injuries, the best timing and route of treatment and the long-term safety and efficacy of the procedure? Previously, equine mesenchymal stem cells (MSCs) have most frequently been isolated from bone marrow (BM) and adipose tissue. However, these cells have limited potential in terms of in vitro proliferation ability and differentiation capacity with increasing donor age and in vitro passage number. In addition, procurement of BM-derived cells in horses requires an invasive BM aspiration procedure which has been associated with pneumopericardium. Fetal adnexa could provide a useful alternative source of MSCs avoiding these limitations. To investigate this, we isolated and characterized presumptive stem cells from the intervascular and perivascular portions of equine umbilical cord matrix using enzymatic digestion. The cells isolated from the intervascular portion showed faster doubling times than cells from the perivascular portion (which are probably more highly differentiated). Cells from both portions expressed MSC mRNA markers (CD29, CD105, CD44, CD166) and were negative for CD34 and MHC-II. Osteogenic, adipogenic, chondrogenic and neurogenic differentiation were confirmed by specific staining and gene expression. To investigate the potential of umbilical cord-derived cells for use in cell therapies, pre-clinical experiments involving labeling of cells with magnetic resonance contrast agents (superparamagnetic iron oxide particles - SPIO - and manganese chloride) and the subsequent in vitro study of these were conducted. The SPIO labeling procedure proved to be an efficient and non toxic tool that merits further investigation and the possible development of in vivo studies.
{"title":"In vitro studies of horse umbilical cord matrix-derived cells: From characterization to labeling for magnetic resonance imaging","authors":"A. Lange-Consiglio, B. Corradetti, L. Rutigliano, F. Cremonesi, D. Bizzaro","doi":"10.2174/1875043501104010120","DOIUrl":"https://doi.org/10.2174/1875043501104010120","url":null,"abstract":"Despite the increasing use of cell-based therapies for equine orthopedic problems, many questions remain to be answered, such as what is: the optimal cell source for particular injuries, the best timing and route of treatment and the long-term safety and efficacy of the procedure? Previously, equine mesenchymal stem cells (MSCs) have most frequently been isolated from bone marrow (BM) and adipose tissue. However, these cells have limited potential in terms of in vitro proliferation ability and differentiation capacity with increasing donor age and in vitro passage number. In addition, procurement of BM-derived cells in horses requires an invasive BM aspiration procedure which has been associated with pneumopericardium. Fetal adnexa could provide a useful alternative source of MSCs avoiding these limitations. To investigate this, we isolated and characterized presumptive stem cells from the intervascular and perivascular portions of equine umbilical cord matrix using enzymatic digestion. The cells isolated from the intervascular portion showed faster doubling times than cells from the perivascular portion (which are probably more highly differentiated). Cells from both portions expressed MSC mRNA markers (CD29, CD105, CD44, CD166) and were negative for CD34 and MHC-II. Osteogenic, adipogenic, chondrogenic and neurogenic differentiation were confirmed by specific staining and gene expression. To investigate the potential of umbilical cord-derived cells for use in cell therapies, pre-clinical experiments involving labeling of cells with magnetic resonance contrast agents (superparamagnetic iron oxide particles - SPIO - and manganese chloride) and the subsequent in vitro study of these were conducted. The SPIO labeling procedure proved to be an efficient and non toxic tool that merits further investigation and the possible development of in vivo studies.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"4 1","pages":"120-133"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68108652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2011-12-30DOI: 10.2174/1875043501104010095
T. Hollweck, Isabel Hartmann, M. Eblenkamp, E. Wintermantel, B. Reichart, P. Überfuhr, G. Eissner
Cardiomyoplasty represents a promising approach for the repair of the injured heart, but is hampered by the availability of appropriate cells. Mesenchymal stem cells derived from the human umbilical cord tissue (UCMSC) can be obtained in large amounts without medical intervention, exhibit self renewal and immunological naivity as well as multipotency. In the present study, different published protocols of cardiac differentiation designed for different stem cell types were compared to differentiate UCMSC into cardiomyocyte-like cells (cUCMSC). Cardiac differentiation of UCMSC was driven by cell treatment with 5-azacytidine, oxytocin as well as by forming of "embryoid bodies". The morphological and immunocytochemical analysis of cUCMSC with an extensive panel of cardiac markers showed that oxytocin is a more potent inducer of cardiac differentiation than 5-azacytidine and the forming of "embryoid bodies". cUCMSC reveal a cardiomyocyte-like structure and the expression of cardiomyocyte associated proteins. The easy accessibility and the ability of UCMSC to differentiate into cells with characteristics of cardiomyocytes render UCMSC an attractive candidate for cell based therapies and cardiac tissue engineering.
{"title":"Cardiac Differentiation of Human Wharton's Jelly Stem Cells –Experimental Comparison of Protocols","authors":"T. Hollweck, Isabel Hartmann, M. Eblenkamp, E. Wintermantel, B. Reichart, P. Überfuhr, G. Eissner","doi":"10.2174/1875043501104010095","DOIUrl":"https://doi.org/10.2174/1875043501104010095","url":null,"abstract":"Cardiomyoplasty represents a promising approach for the repair of the injured heart, but is hampered by the availability of appropriate cells. Mesenchymal stem cells derived from the human umbilical cord tissue (UCMSC) can be obtained in large amounts without medical intervention, exhibit self renewal and immunological naivity as well as multipotency. In the present study, different published protocols of cardiac differentiation designed for different stem cell types were compared to differentiate UCMSC into cardiomyocyte-like cells (cUCMSC). Cardiac differentiation of UCMSC was driven by cell treatment with 5-azacytidine, oxytocin as well as by forming of \"embryoid bodies\". The morphological and immunocytochemical analysis of cUCMSC with an extensive panel of cardiac markers showed that oxytocin is a more potent inducer of cardiac differentiation than 5-azacytidine and the forming of \"embryoid bodies\". cUCMSC reveal a cardiomyocyte-like structure and the expression of cardiomyocyte associated proteins. The easy accessibility and the ability of UCMSC to differentiate into cells with characteristics of cardiomyocytes render UCMSC an attractive candidate for cell based therapies and cardiac tissue engineering.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"4 1","pages":"95-102"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68108957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-11-05DOI: 10.2174/1875043501003010036
S. Garbuzova-Davis, P. Bickford
Nutritional approaches to the treatment of aging and neurodegenerative diseases have been shown to have potential benefits. Fruits or vegetables provide a cocktail of phytochemicals with multiple actions. Spirulina, a blue green alga used for thousands of years as a food source by the Aztecs, is known to contain large amounts of β-carotene and several phycocyanins with potent antioxidant and anti-inflammatory effects. We examined neuroprotective effects of a spirulina 0.1% supplemented diet in the G93A SOD1 mouse model of ALS beginning at 5 weeks of age and continuing for 10 weeks. Spirulina dietary supplement significantly maintained body weight and extension reflex, and reduced inflammatory markers and motor neuron degeneration in G93A mice. These findings provide initial evidence that nutrition supplementation with spirulina has a neuroprotective support for dying motor neurons. A spirulina supplemented diet may be a potential alternative or adjunctive treatment for ALS.
{"title":"Short Communication: Neuroprotective Effect of Spirulina in a Mouse Model of ALS","authors":"S. Garbuzova-Davis, P. Bickford","doi":"10.2174/1875043501003010036","DOIUrl":"https://doi.org/10.2174/1875043501003010036","url":null,"abstract":"Nutritional approaches to the treatment of aging and neurodegenerative diseases have been shown to have potential benefits. Fruits or vegetables provide a cocktail of phytochemicals with multiple actions. Spirulina, a blue green alga used for thousands of years as a food source by the Aztecs, is known to contain large amounts of β-carotene and several phycocyanins with potent antioxidant and anti-inflammatory effects. We examined neuroprotective effects of a spirulina 0.1% supplemented diet in the G93A SOD1 mouse model of ALS beginning at 5 weeks of age and continuing for 10 weeks. Spirulina dietary supplement significantly maintained body weight and extension reflex, and reduced inflammatory markers and motor neuron degeneration in G93A mice. These findings provide initial evidence that nutrition supplementation with spirulina has a neuroprotective support for dying motor neurons. A spirulina supplemented diet may be a potential alternative or adjunctive treatment for ALS.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"3 1","pages":"36-41"},"PeriodicalIF":0.0,"publicationDate":"2010-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68108692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-09-03DOI: 10.2174/1875043501003010028
A. J. Kim, H. D. Adkisson, M. Wendland, Mitchell S. Seyedin, S. Berven, J. Lotz
{"title":"Juvenile Chondrocytes May Facilitate Disc Repair~!2010-01-08~!2010-04-08~!2010-08-23~!","authors":"A. J. Kim, H. D. Adkisson, M. Wendland, Mitchell S. Seyedin, S. Berven, J. Lotz","doi":"10.2174/1875043501003010028","DOIUrl":"https://doi.org/10.2174/1875043501003010028","url":null,"abstract":"","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"3 1","pages":"28-35"},"PeriodicalIF":0.0,"publicationDate":"2010-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68108678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-04-28DOI: 10.2174/1875043501003010018
Kayoko Tono-Okada, Y. Okada, M. Masuda, Akio Hoshi, A. Akatsuka, A. Teramoto, K. Abe, T. Tamaki
In order to hold non-adhesive type cells while maintaining cellular interactions and various autocrine/paracrine factors, a micro 3D culture system using Hyaluronan (HA)-type I collagen capsules was investigated as a possible scaffold for cell transplantation. Skeletal muscle-derived enzymatically extracted cells, which include numerous non-adhesive type stem cells were cultured in conventional liquid DMEM with and without encapsulation in HA-collagen capsules, and cellular proliferation/differentiation were compared. Results indicate that encapsulation does not disturb any cellular proliferation/differentiation after 7 days of culture. Gradual increases in vascular endothelial growth factor are also confirmed in HA-collagen culture, which may be induced by slower diffusion of autocrine/paracrine factors in the capsule and may benefit cellular proliferation/differentiation. Cell-holding capacity of encapsulation was also tested by in vivo transplantation into wide-open muscle scars without fascia. Encapsulation significantly contributes to higher donor cell implantation ratio and damaged muscle mass recovery than that of non-capsulation.
{"title":"Micro 3D Culture System using Hyaluronan-Collagen Capsule for Skeletal Muscle-Derived Stem Cells","authors":"Kayoko Tono-Okada, Y. Okada, M. Masuda, Akio Hoshi, A. Akatsuka, A. Teramoto, K. Abe, T. Tamaki","doi":"10.2174/1875043501003010018","DOIUrl":"https://doi.org/10.2174/1875043501003010018","url":null,"abstract":"In order to hold non-adhesive type cells while maintaining cellular interactions and various autocrine/paracrine factors, a micro 3D culture system using Hyaluronan (HA)-type I collagen capsules was investigated as a possible scaffold for cell transplantation. Skeletal muscle-derived enzymatically extracted cells, which include numerous non-adhesive type stem cells were cultured in conventional liquid DMEM with and without encapsulation in HA-collagen capsules, and cellular proliferation/differentiation were compared. Results indicate that encapsulation does not disturb any cellular proliferation/differentiation after 7 days of culture. Gradual increases in vascular endothelial growth factor are also confirmed in HA-collagen culture, which may be induced by slower diffusion of autocrine/paracrine factors in the capsule and may benefit cellular proliferation/differentiation. Cell-holding capacity of encapsulation was also tested by in vivo transplantation into wide-open muscle scars without fascia. Encapsulation significantly contributes to higher donor cell implantation ratio and damaged muscle mass recovery than that of non-capsulation.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2010-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68108644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2010-04-07DOI: 10.2174/1875043501003010010
Bettina Bareiss, M. Ghorbani, Fengfu Li, J. A. Blake, J. Scaiano, Jin Zhang, Chao Deng, Kimberley Merrett, J. Harden, F. Diaz-Mitoma, M. Griffith
Herpes simplex virus (HSV) infection is the most common cause of corneal blindness in the Western world. Despite effective anti-viral drugs such as acyclovir (ACV), disease recurrence due to the virus establishing latency within the corneal nerves and possibly cells makes treatment very challenging. Furthermore, although effective, current systemic and topical preparations of anti-viral drugs do not appear to deliver sufficient quantities to the cornea to prevent reactivation. Current treatment for HSV vision loss is transplantation with donor corneas, but the surgery itself can reactivate viruses. We examined the feasibility of preventing viral reactivation during surgery, by sustained delivery of ACV introduced during corneal transplantation surgery, through encapsulation of the drug within silica (SiO2) nanoparticles (NP) incorporated into biosynthetic alternatives to donor corneas. We show that incorporation of NPs did not affect optical clarity of the collagen-based corneal substitutes nor their biocompatibility. NP-encapsulation effectively sustained ACV release from the biosynthetic implants over 10 days, compared to free ACV incorporated directly into the hydrogel constructs. The NP-enabled sustained release resulted in effective prevention of virally-induced cell death, not observed with the free drug. This early model demonstrates the feasibility of using biomimetic corneal substitutes that incorporate a drug release system (e.g. silica nanoparticles encapsulating ACV) as future alternatives to human donor tissue grafts, for transplantation of HSV-infected corneas.
{"title":"Controlled Release of Acyclovir Through Bioengineered Corneal Implants with Silica Nanoparticle Carriers~!2009-08-29~!2010-01-05~!2010-03-18~!","authors":"Bettina Bareiss, M. Ghorbani, Fengfu Li, J. A. Blake, J. Scaiano, Jin Zhang, Chao Deng, Kimberley Merrett, J. Harden, F. Diaz-Mitoma, M. Griffith","doi":"10.2174/1875043501003010010","DOIUrl":"https://doi.org/10.2174/1875043501003010010","url":null,"abstract":"Herpes simplex virus (HSV) infection is the most common cause of corneal blindness in the Western world. Despite effective anti-viral drugs such as acyclovir (ACV), disease recurrence due to the virus establishing latency within the corneal nerves and possibly cells makes treatment very challenging. Furthermore, although effective, current systemic and topical preparations of anti-viral drugs do not appear to deliver sufficient quantities to the cornea to prevent reactivation. Current treatment for HSV vision loss is transplantation with donor corneas, but the surgery itself can reactivate viruses. We examined the feasibility of preventing viral reactivation during surgery, by sustained delivery of ACV introduced during corneal transplantation surgery, through encapsulation of the drug within silica (SiO2) nanoparticles (NP) incorporated into biosynthetic alternatives to donor corneas. We show that incorporation of NPs did not affect optical clarity of the collagen-based corneal substitutes nor their biocompatibility. NP-encapsulation effectively sustained ACV release from the biosynthetic implants over 10 days, compared to free ACV incorporated directly into the hydrogel constructs. The NP-enabled sustained release resulted in effective prevention of virally-induced cell death, not observed with the free drug. This early model demonstrates the feasibility of using biomimetic corneal substitutes that incorporate a drug release system (e.g. silica nanoparticles encapsulating ACV) as future alternatives to human donor tissue grafts, for transplantation of HSV-infected corneas.","PeriodicalId":88761,"journal":{"name":"The open tissue engineering and regenerative medicine journal","volume":"3 1","pages":"10-17"},"PeriodicalIF":0.0,"publicationDate":"2010-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68108630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：